PMID- 37554498
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230810
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 10
DP  - 2023
TI  - Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung 
      cancer: a meta-analysis.
PG  - 1139248
LID - 10.3389/fmed.2023.1139248 [doi]
LID - 1139248
AB  - PURPOSE: This meta-analysis was exerted in assessing the anticancer efficacy and 
      safety of nab-paclitaxel (nab-P) when combined with platinum compound agents for 
      therapy in patients with non-small cell lung cancer (NSCLC). METHOD: We 
      systematically searched the following seven electronic databases: PubMed, 
      Cochrane Library, Web of Science, Embase, CNKI, Wan Fang, and China Science and 
      Technology Journal Data. Randomized comparative clinical [randomized controlled 
      clinical trial (RCT)] studies on nab-P plus platinum and carboplatin or cisplatin 
      in combination with conventional chemotherapy agents or traditional paclitaxel 
      were searched. RESULTS: A total of 19 RCT studies involving 6,011 patients were 
      analyzed. The primary outcome includes the overall response rate (ORR), overall 
      survival (OS), and progression-free survival (PFS). The secondary outcome 
      includes adverse events (AEs). Nab-P combined with platinum 
      (carboplatin/cisplatin) had a better ORR [odds ratio (OR) = 1.66, 95% confidence 
      interval (CI) (1.34, 2.05), p < 0.001] and improved PFS [hazard ratio (HR) = 
      0.84, 95% CI: (0.74, 0.94), p = 0.01] and OS [HR = 0.86, 95% CI: (0.78, 0.96), p 
      = 0.008] in NSCLC patients. ORR [OR = 2.18, 95% CI: (1.07, 4.43)], PFS [HR = 
      0.62, 95% CI: (0.40, 0.97)], and OS [HR = 0.63, 95% CI: (0.49, 0.81)] were 
      significantly improved among patients aged >70 years, and ORR [OR = 1.80, 95% CI: 
      (1.20, 2.70)] and PFS [HR = 0.74, 95% CI: (0.56, 0.97)] were significantly 
      elevated with SCC rate >/=65% in NSCLC patients (all p > 0.05). Among the adverse 
      effects, the prevalence of neutropenia, neuralgia, and arthralgia/myalgia (>/= 
      grade 3) compared to that of the control group. On the other hand, the prevalence 
      of anemia and thrombocytopenia was higher in the nab-P plus platinum 
      (carboplatin/cisplatin) compared to that of controls. It is worth noting that 
      fatigue did not show statistical significance. CONCLUSION: Nab-P in combination 
      with carboplatin/cisplatin regimen improves efficacy and tolerability in patients 
      with NSCLC. SYSTEMATIC REVIEW REGISTRATION: http://www.crd.york.ac.uk/PROSPERO/, 
      identifier: CRD42022288499.
CI  - Copyright (c) 2023 Tan, Li, Hu, Yue, Zeng, Zeng, Chen, Zhao and Xiao.
FAU - Tan, Tianying
AU  - Tan T
AD  - College of Clinical Medicine, Guizhou University of Traditional Chinese Medicine, 
      Guiyang, Guizhou, China.
FAU - Li, Shuangshuang
AU  - Li S
AD  - College of Clinical Medicine, Guizhou University of Traditional Chinese Medicine, 
      Guiyang, Guizhou, China.
FAU - Hu, Wenting
AU  - Hu W
AD  - College of Clinical Medicine, Guizhou University of Traditional Chinese Medicine, 
      Guiyang, Guizhou, China.
FAU - Yue, Tinghui
AU  - Yue T
AD  - College of Clinical Medicine, Guizhou University of Traditional Chinese Medicine, 
      Guiyang, Guizhou, China.
FAU - Zeng, Qi
AU  - Zeng Q
AD  - School of Basic Medicine, Guizhou University of Traditional Chinese Medicine, 
      Guiyang, Guizhou, China.
FAU - Zeng, Xingling
AU  - Zeng X
AD  - Clinical Medicine College, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, China.
FAU - Chen, Xiaochao
AU  - Chen X
AD  - Colorectal and Anal Surgery, Chengdu Anorectal Hospital, Chengdu, Sichuan, China.
FAU - Zhao, Xiangdong
AU  - Zhao X
AD  - Colorectal and Anal Surgery, Shenzhen Traditional Chinese Medicine Hospital, 
      Shenzhen, China.
FAU - Xiao, Tianbao
AU  - Xiao T
AD  - Colorectal and Anal Surgery, The First Affiliated Hospital of Guizhou University 
      of Traditional Chinese Medicine, Guiyang, Guizhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20230724
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC10406255
OTO - NOTNLM
OT  - chemotherapy
OT  - efficacy
OT  - meta-analysis
OT  - nab-paclitaxel
OT  - non-small cell lung cancer
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/09 06:43
MHDA- 2023/08/09 06:44
PMCR- 2023/07/24
CRDT- 2023/08/09 04:01
PHST- 2023/01/06 00:00 [received]
PHST- 2023/06/19 00:00 [accepted]
PHST- 2023/08/09 06:44 [medline]
PHST- 2023/08/09 06:43 [pubmed]
PHST- 2023/08/09 04:01 [entrez]
PHST- 2023/07/24 00:00 [pmc-release]
AID - 10.3389/fmed.2023.1139248 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2023 Jul 24;10:1139248. doi: 10.3389/fmed.2023.1139248. 
      eCollection 2023.